Stockscreener 앱 받기
3.72
0.80%
-0.03
시간 외 거래:
3.71
-0.01
-0.27%
전일 마감가:
$3.75
열려 있는:
$3.61
하루 거래량:
325.85K
Relative Volume:
1.43
시가총액:
$245.79M
수익:
$7.69M
순이익/손실:
$-17.65M
주가수익비율:
-9.9386
EPS:
-0.3743
순현금흐름:
$-15.72M
1주 성능:
+9.41%
1개월 성능:
+0.81%
6개월 성능:
+75.47%
1년 성능:
+104.40%
1일 변동 폭
$3.41
$3.775
1주일 범위
$3.21
$3.95
52주 변동 폭
$1.30
$4.75
에이다진 Stock (ADAG) Company Profile
Compare ADAG vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
3.72 | 247.77M | 7.69M | -17.65M | -15.72M | -0.3743 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
에이다진 Stock (ADAG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 개시 | Guggenheim | Buy |
| 2025-08-06 | 개시 | Leerink Partners | Outperform |
| 2025-01-31 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-25 | 개시 | China Renaissance | Buy |
| 2021-03-08 | 개시 | Goldman | Buy |
| 2021-03-08 | 개시 | Jefferies | Buy |
| 2021-03-08 | 개시 | Morgan Stanley | Overweight |
모두보기
에이다진 주식(ADAG)의 최신 뉴스
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer - sharewise.com
WuXi entities report 3.49M-share stake in Adagene (NASDAQ: ADAG) - Stock Titan
ADAG Stock Price, Quote & Chart | ADAGENE INC-ADR (NASDAQ:ADAG) - ChartMill
Adagene Inc. to Participate in Stifel Annual Virtual Oncology Event and Jefferies Global Healthcare Conference - Quiver Quantitative
Adagene to Participate in Two Upcoming Investor Conferences - marketscreener.com
Cancer antibody developer Adagene speaks at two investor events - Stock Titan
Janus Henderson (ADAG) reports 6.67M ADRs, 10.1% stake (04/30/2026) - Stock Titan
Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT) - The Globe and Mail
Adagene announces pricing of $70M public offering of ADS - MSN
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Sees Large Increase in Short Interest - MarketBeat
Adagene and Incyte Partner to Develop Colorectal Cancer Therapy - HarianBasis.co
Qinghai Zhao Net Worth (2026) - GuruFocus
Adagene reports trial data for cancer drug muzastotug combos By Investing.com - Investing.com South Africa
Adagene reports trial data for cancer drug muzastotug combos - Investing.com
Experimental Adagene drug lifts liver cancer response to 66.7% - Stock Titan
Adagene (NASDAQ: ADAG) shows strong AACR 2026 data for muzastotug combo therapies - Stock Titan
Adagene Presents Two Posters at AACR 2026 with New Data - GlobeNewswire
Adagene Looks Attractive With ADG126 And Validating Partnerships (NASDAQ:ADAG) - Seeking Alpha
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Adagene appoints Peter Lebowitz to advisory board - Investing.com
Adagene appoints Peter Lebowitz to advisory board By Investing.com - Investing.com India
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board - Bitget
Executive behind 13 cancer drugs joins Adagene advisory board - Stock Titan
Analysts Offer Predictions for Adagene FY2026 Earnings - MarketBeat
H.C. Wainwright reiterates Adagene stock rating on trial data By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Adagene stock rating on trial data - Investing.com
Guggenheim Issues Positive Forecast for Adagene (NASDAQ:ADAG) Stock Price - MarketBeat
Guggenheim raises Adagene stock price target on cancer drug data - Investing.com
Guggenheim raises Adagene stock price target on cancer drug data By Investing.com - Investing.com South Africa
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs - Sahm
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Sahm
Leerink raises Adagene stock price target to $8 on combination data - Investing.com India
[424B5] Adagene Inc. Prospectus Supplement (Debt Securities) - stocktitan.net
Leerink raises Adagene stock price target to $8 on combination data By Investing.com - Investing.com South Africa
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update - wahanariau.com
Adagene sets $3.75 per ADS price for $70M offering - MSN
Why Is ADAG Stock Tanking Today? - Stocktwits
Adagene prices $70 million public offering at $3.75 per ADS By Investing.com - Investing.com India
Adagene Posts Strong Muzastotug Data and Incyte Collaboration in MSS Colorectal Cancer - TipRanks
Adagene prices $70 million public offering at $3.75 per ADS - Investing.com
Adagene Prices US$70 Million ADS Offering to Bolster Cancer Immunotherapy Pipeline - TipRanks
Adagene reports 31% response rate in colorectal cancer trial By Investing.com - Investing.com India
Adagene reports 31% response rate in colorectal cancer trial - investing.com
Adagene (Nasdaq: ADAG) prices $70M ADS sale at 30-day VWAP - Stock Titan
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Bitget
Adagene (ADAG) launches ADS offering to fund ADG126 and pipeline - Stock Titan
Updated Data from Phase 1b/2 Study of Muzastotug in - GlobeNewswire
Adagene (ADAG) reports stronger 20 mg/kg muzastotug results and Fast Track status - Stock Titan
에이다진 (ADAG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):